DOCSLIB.ORG

A Reciprocal Feedback Between the PDZ Binding Kinase and Androgen Receptor Drives Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Reciprocal Feedback Between the PDZ Binding Kinase and Androgen Receptor Drives Prostate Cancer Oncogene (2019) 38:1136–1150 https://doi.org/10.1038/s41388-018-0501-z ARTICLE A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer 1 2 3 4 3 5,6 Anne Y. Warren ● Charlie E. Massie ● Kate Watt ● Katarina Luko ● Folake Orafidiya ● Luke A. Selth ● 7 1 8 8 1 8 Hisham Mohammed ● Brinder S. Chohan ● Suraj Menon ● Ajoeb Baridi ● Wanfeng Zhao ● Carles Escriu ● 4 8 8 8 8 8 Thanakorn Pungsrinont ● Clive D’Santos ● Xiaoping Yang ● Chris Taylor ● Arham Qureshi ● Vincent R. Zecchini ● 8 9 10,11 8 5,6 3 Greg L. Shaw ● Scott M. Dehm ● Ian G. Mills ● Jason S. Carroll ● Wayne D. Tilley ● Iain J. McEwan ● 4 8,11 8,11,12 Aria Baniahmad ● David E. Neal ● Mohammad Asim Received: 16 March 2018 / Revised: 17 July 2018 / Accepted: 16 August 2018 / Published online: 20 September 2018 © The Author(s) 2018. This article is published with open access Abstract Elucidation of mechanisms underlying the increased androgen receptor (AR) activity and subsequent development of aggressive prostate cancer (PrCa) is pivotal in developing new therapies. Using a systems biology approach, we interrogated the AR-regulated proteome and identified PDZ binding kinase (PBK) as a novel AR-regulated protein that regulates full- 1234567890();,: 1234567890();,: length AR and AR variants (ARVs) activity in PrCa. PBK overexpression in aggressive PrCa is associated with early biochemical relapse and poor clinical outcome. In addition to its carboxy terminus ligand-binding domain, PBK directly interacts with the amino terminus transactivation domain of the AR to stabilise it thereby leading to increased AR protein expression observed in PrCa. Transcriptome sequencing revealed that PBK is a mediator of global AR signalling with key roles in regulating tumour invasion and metastasis. PBK inhibition decreased growth of PrCa cell lines and clinical specimen cultured ex vivo. We uncovered a novel interplay between AR and PBK that results in increased AR and ARVs expression that executes AR-mediated growth and progression of PrCa, with implications for the development of PBK inhibitors for the treatment of aggressive PrCa. Introduction These authors contributed equally: David E. Neal, Mohammad Asim Prostate cancer (PrCa) is a major cancer responsible for Electronic supplementary material The online version of this article male fatalities worldwide [1]. The growth and survival of (https://doi.org/10.1038/s41388-018-0501-z) contains supplementary PrCa is driven by the male sex hormone androgens that act material, which is available to authorized users. * Mohammad Asim 6 Freemasons Foundation Centre for Men’s Health, School of [email protected] Medicine, Faculty of Health Sciences, University of Adelaide, [email protected] Adelaide, Australia 7 Cancer Early Detection Advanced Research Center, Knight 1 Department of Pathology, Addenbrooke’s Cambridge University Cancer Institute, OHSU, Portland, USA Hospital, Cambridge, UK 8 Cancer Research UK Cambridge Institute, University of 2 Early Detection Programme, Cancer Research UK Cambridge Cambridge, Cambridge, UK Centre, Department of Oncology, University of Cambridge, Cambridge, UK 9 Masonic Cancer Center, University of Minnesota, Minneapolis, USA 3 Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK 10 Prostate Cancer UK/Movember Centre of Excellence, CCRCB, Queens University, Belfast, UK 4 Institute of Human Genetics, Jena University Hospital, Jena, Germany 11 Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK 5 Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, Faculty of Health Sciences, University of Adelaide, 12 Department of Clinical & Experimental Medicine, Faculty of Adelaide, Australia Health & Medical Sciences, University of Surrey, Guildford, UK A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer 1137 by binding to the androgen receptor (AR) [2, 3]. Conse- NTD and LBD of AR to directly regulate the stability and quently, androgen-deprivation therapy (ADT) is used as a function of both full-length AR and ARVs. Inhibition of first-line therapy for the treatment of locally advanced or PBK activity destabilises AR and decreases PrCa growth metastatic PrCa. ADT comprises; luteinizing hormone- and metastasis. These results provide novel insights into the releasing hormone (LHRH) analogues that block androgen role of androgen-induced pathways in PrCa revealing PBK production, anti-androgens such as bicalutamide and enza- as a key effector through which AR manifest its oncogenic lutamide that antagonise androgen binding to the AR, and function in PrCa. abiraterone that inhibits the androgen biosynthesis pathway [4, 5]. ADT is initially effective but resistance is common and Results this leads to the development of aggressive incurable dis- ease known as castration-resistant prostate cancer (CRPC) Identification of PBK as a novel AR target in PrCa [6]. CRPC is often driven by the reactivation of AR sig- nalling through multiple molecular mechanisms, which Mass spectrometry identified the AR-regulated proteome of include amplification and gain-of-function mutations of the the CRPC cells following AR knockdown using a pre- AR gene, gain-of-function mutations in the androgen sig- validated set of four different siRNAs as used earlier [14]or nalling pathway [7], and the emergence of constitutively AR inhibition with the AR antagonist, bicalutamide. Sup- active AR splice forms known as AR variants (ARVs; e.g., porting the robustness of the data, a significant correlation ARV7). ARVs are devoid of the ligand-binding domain was found between proteins regulated by AR knockdown (LBD) and thus such variants cannot be targeted by ADT and bicalutamide treatment (Pearson r2 = 0.51). The protein [8, 9]. Notably, the AR amino terminus domain (NTD) is levels of known androgen-upregulated targets were down- the prime driver of PrCa growth, thus making it a potential regulated by both AR knockdown and bicalutamide treat- drug target [10, 11]. ment, whereas androgen-repressed proteins were In addition to direct changes to the AR, another upregulated by both AR treatments (n = 514) (Fig. 1a and mechanism underlying CRPC growth is increased activity Table S1). and/or expression of AR co-activators [12–14]. Yet another A core set of 77 AR-regulated proteins common between hallmark of AR signalling in PrCa is the integrated feed- AR knockdown and bicalutamide treatment was identified forward and feedback circuits that facilitate pro-growth that showed consistent changes in the same direction, signalling as exemplified by the reciprocal positive feed- including known AR-regulated targets such as FKBP5 and back between AR and choline kinase alpha signalling [14, FASN (Figure S1A and Table S2). This analysis also pro- 15] and reciprocal negative feedback between AR and poly vided evidence that the vesicle transport protein NIPS- ADP-Ribose polymerase-1 signalling [16]. Androgens can NAP3A is an AR-repressed target. Among the factors in the also negatively regulate AR mRNA expression by recruit- proteome data that were commonly downregulated by both ment of AR to a repressive element in intron 2 of the AR AR knockdown and bicalutamide treatment was PBK (Fig. gene [17, 18]. Despite decreasing AR mRNA levels, 1a and Figure S1A). Supporting these findings, PBK tran- androgens promote AR stabilisation leading to overall script and protein levels decreased following AR knock- increase in AR protein expression. This example highlights down (Fig. 2b, Figures S1B and S5A) and AR-binding sites the critical need to analyse the androgen-regulated proteome were identified at the enhancer upstream of the PBK gene in order to characterise androgen-regulated changes at (Figure S1C). PBK expression in situ was also androgen- protein level in PrCa. regulated in a series [19] of human prostate tissue com- In order to understand how AR is stabilised and pro- prising benign prostate tissues and PrCa samples from motes PrCa growth, it is imperative to identify clinically untreated men (n = 20) or those treated with androgen relevant AR targets, both up- and downstream of AR sig- inhibitor degarelix (a LHRH agonist that blocks testicular nalling. Here, we generated androgen-regulated proteome androgen synthesis) for 7 days (n = 27) (Fig. 1c). Nuclear data sets to comprehensively identify effectors of androgen PBK staining was significantly higher in PrCa tissues signalling and identified PDZ binding kinase (PBK) as an compared with benign control tissues from untreated men AR-regulated factor in vitro and in vivo in PrCa that inte- ((p < 0.0001) (Fig. 1c, d). Degarelix treatment decreased the grates AR signalling with PrCa growth. In men with PrCa, nuclear levels of PBK in the treated tumours compared with PBK is androgen-regulated and localised in the tumour cell untreated patients (p < 0.01), with 45% of degarelix-treated nucleus. PBK overexpression is associated with poor dis- cases having no detectable expression of PBK in compar- ease outcome and clinical progression. We further uncover ison to 15% of untreated cases. Overall, cytosolic PBK PBK interactome and identify a crucial reciprocal feedback levels were lower compared to nuclear levels in all tissues between PBK and AR, whereby PBK interacts with both the tested, whereas there was no significant difference in 1138 A. Y. Warren et al. A B Protein profiles (log2 ratio) AR siNT si 1.0 Cor = 0.51 1.0 0.32 AR 0.5 β-Actin 0.0 1.0 0.31 Bicalutamide PBK -0.5 Ponceau -1.5-1.0 -0.5
Load more

Recommended publications
  • Functional Transcriptomic Annotation and Protein–Protein Interaction
    Breast Cancer Research and Treatment https://doi.org/10.1007/s10549-017-4652-3 PRECLINICAL STUDY Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer Miriam Nuncia‑Cantarero1 · Sandra Martinez‑Canales2 · Fernando Andrés‑Pretel2 · Gabriel Santpere3 · Alberto Ocaña2 · Eva Maria Galan‑Moya1 Received: 18 October 2017 / Accepted: 29 December 2017 © The Author(s) 2018. This article is an open access publication Abstract Purpose Although obesity is a risk factor for breast cancer, little efort has been made in the identifcation of druggable molecular alterations in obese–breast cancer patients. Tumors are controlled by their surrounding microenvironment, in which the adipose tissue is a main component. In this work, we intended to describe molecular alterations at a transcriptomic and protein–protein interaction (PPI) level between obese and non-obese patients. Methods and results Gene expression data of 269 primary breast tumors were compared between normal-weight (BMI < 25, n = 130) and obese (IMC > 30, n = 139) patients. No signifcant diferences were found for the global breast cancer popula- tion. However, within the luminal A subtype, upregulation of 81 genes was observed in the obese group (FC ≥ 1.4). Next, we explored the association of these genes with patient outcome, observing that 39 were linked with detrimental outcome. Their PPI map formed highly compact cluster and functional annotation analyses showed that cell cycle, cell proliferation, cell diferentiation, and cellular response to extracellular stimuli were the more altered functions. Combined analyses of genes within the described functions are correlated with poor outcome.
    [Show full text]
  • Network-Based Genetic Profiling, and Therapeutic Target Identification Of
    bioRxiv preprint doi: https://doi.org/10.1101/480632; this version posted November 29, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Network-based genetic profiling, and therapeutic target identification of Thyroid Cancer 1st Md. Ali Hossain 2nd Tania Akter Asa 3rd Julian Quinn 4rdMd. Mijanur Rahman Dept. of CSE Dept. of EEE Bone biology divisions Dept. of CSE MIU, Jahangirnagar University Islamic University Garvan Institute of Medical Research JKKNIU Dhaka, Bangladesh Kushtia, Bangladesh Sydney, Australia Bangladesh ali:cse:bd@gmail:com tania:eee:iu@gmail:com j:quinn@garvan:org:au mijan cse@yahoo:com 5th Fazlul Huq 6th Mohammad Ali Moni Biomedical Sciences, Faculty of Medicine and Health Biomedical Sciences, Faculty of Medicine and Health The University of Sydney The University of Sydney Sydney, Australia Sydney, Australia fazlul:huq@sydney:edu:au mohammad:moni@sydney:edu:au Abstract—Molecular mechanisms that underlie the pathogene- I. INTRODUCTION sis and progression of malignant thyroid cancer (TC) are poorly understood. In this study, we employed network-based integrative Thyroid cancer (TC) is the most common endocrine ma- analyses of TC lesions to identify key molecules that are possible lignant disease [24], and although it has a relatively low hub genes and proteins in molecular pathways active in TC. We thus studied a microarray gene expression dataset (GSE82208, mortality rate compared to most other common metastatic n=52) that compared TC to benign thyroid tumours (follicular diseases its incidence is rising and is now the fifth most thyroid adenomas) in order to identify differentially expressed common cancer disease in women, notably affecting those genes (DEGs) in TC.
    [Show full text]
  • Identi Cation of Molecular Markers Associated with Ovarian Cancer
    Identication of Molecular Markers Associated With Ovarian Cancer Prognosis Using Bioinformatics Analysis Li Chuang Shengjing Hospital of China Medical University https://orcid.org/0000-0002-6346-2857 Yuan Lyu Shengjing Hospital of China Medical University Caixia Liu ( [email protected] ) https://orcid.org/0000-0001-7019-0266 Primary research Keywords: bioinformatics analysis, differentially expressed genes, Gene Expression Omnibus database, ovarian cancer, PDZ-binding kinase Posted Date: February 21st, 2020 DOI: https://doi.org/10.21203/rs.2.24152/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Background Ovarian cancer is associated with a high mortality rate worldwide. However, the pathogenesis, clinicopathological features, and genetic mechanisms of ovarian cancer are still unclear, and it is essential to identify prognostic markers for its clinical diagnosis and treatment. Here, we utilized bioinformatic analysis to identify potential genes involved in mediating BRCA1 expression to elucidate the potential mechanisms underlying ovarian cancer. Methods Gene expression proling (GSE14407) was performed to identify differentially expressed genes (DEGs) and analyze the weighted gene co-expression network. We selected the key module that was signicantly associated with BRCA1 expression and performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for genes in the hub module. We then screened the hub genes utilizing the Search Tool for the Retrieval of Interacting Genes Database (STRING) and Molecular Complex Detection (MCODE) plug-in in Cytoscape. We validated gene expression levels through The Cancer Genome Atlas and GTEx databases for hub genes and screened genes that were related to overall survival in patients with ovarian cancer using the Kaplan-Meier plotter database.
    [Show full text]
  • A Resource for Exploring the Understudied Human Kinome for Research and Therapeutic
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted March 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. A resource for exploring the understudied human kinome for research and therapeutic opportunities Nienke Moret1,2,*, Changchang Liu1,2,*, Benjamin M. Gyori2, John A. Bachman,2, Albert Steppi2, Clemens Hug2, Rahil Taujale3, Liang-Chin Huang3, Matthew E. Berginski1,4,5, Shawn M. Gomez1,4,5, Natarajan Kannan,1,3 and Peter K. Sorger1,2,† *These authors contributed equally † Corresponding author 1The NIH Understudied Kinome Consortium 2Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, USA 3 Institute of Bioinformatics, University of Georgia, Athens, GA, 30602 USA 4 Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 5 Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC 27599, USA † Peter Sorger Warren Alpert 432 200 Longwood Avenue Harvard Medical School, Boston MA 02115 [email protected] cc: [email protected] 617-432-6901 ORCID Numbers Peter K. Sorger 0000-0002-3364-1838 Nienke Moret 0000-0001-6038-6863 Changchang Liu 0000-0003-4594-4577 Benjamin M. Gyori 0000-0001-9439-5346 John A. Bachman 0000-0001-6095-2466 Albert Steppi 0000-0001-5871-6245 Shawn M.
    [Show full text]
  • Reproductionresearch
    REPRODUCTIONRESEARCH Dielectrophoretic behavior of in vitro-derived bovine metaphase II oocytes and zygotes and its relation to in vitro embryonic developmental competence and mRNA expression pattern Salilew-Wondim Dessie, Franca Rings, Michael Ho¨lker, Markus Gilles, Danyel Jennen, Ernst Tholen, Vitezslav Havlicek1, Urban Besenfelder1, Vladimir L Sukhorukov2, Ulrich Zimmermann2, Joerg M Endter2, Marc-Andre´ Sirard3, Karl Schellander and Dawit Tesfaye Animal Breeding and Husbandry Group, Institute of Animal Science, University of Bonn, Endenicher Allee 15, Bonn, Germany, 1University of Veterinary Medicine, Veterina¨r platz 1, A-1210 Vienna, Austria, 2Biotechnology center, University of Wuerzburg, D-97074, Wuerzburg, Germany and 3De´partment des Science Animales, Centre de Recherche en Biologie de la Reproduction, Universite´ Laval, G1K7p4, Quebec, Canada Correspondence should be addressed to D Tesfaye; Email: [email protected] Abstract Selecting developmentally competent oocytes and zygotes based on their morphology is more often influenced by personal judgments and lacks universal standards. Therefore, this experiment was conducted to investigate the rate of development and mRNA level of dielectrophoretically separated oocytes and zygotes to validate dielectrophoresis (DEP) as non-invasive option for C K selection of oocytes and zygotes. In the first experiment, metaphase II oocytes with (PB ) and without (PB ) first polar body and zygotes were subjected to DEP at 4 MHz and 450 mm electrode distance and classified into fast, very fast, slow, and very slow depending on the time elapsed to reach one of the electrodes in the electric field. Parthenogenetic activation was employed to monitor the embryonic development of dielectrophoretically classified oocytes. The result revealed that at 6 and 7 days of post- C K activation, the blastocyst rate of very slow dielectrophoretic PB and PB oocytes was significantly (P!0.05) lower than other groups.
    [Show full text]
  • Screening and Identification of Key Biomarkers in Prostate Cancer Using Bioinformatics
    MOLECULAR MEDICINE REPORTS 21: 311-319, 2020 Screening and identification of key biomarkers in prostate cancer using bioinformatics SONG LI, JUNQING HOU and WEIBO XU Department of Urology, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, P.R. China Received May 10, 2019; Accepted October 16, 2019 DOI: 10.3892/mmr.2019.10799 Abstract. Prostate cancer (PCa) is the second most common number of unnecessary biopsies performed without reducing cancer amongst males worldwide. In the current study, patient mortality (6). Previous studies have associated the microarray datasets GSE3325 and GSE6919 from the Gene tribbles pseudokinase 1 gene with the development of a Expression Omnibus database were screened to identify number of tumors, including colorectal leukemia and hepato- candidate genes that are associated with the progression of cellular cancers (7-9). It has been shown that transmembrane PCa. A total of 273 differentially expressed genes (DEGs) protease, serine 2:ETS-related gene (TMPRSS2:ERG) fusion were identified, which included 173 downregulated genes is associated with diagnosing PCa in urine samples and and 100 upregulated genes, and a protein-protein interaction DNA‑based molecular templates (10). However, due to the network was constructed using Search Tool for the Retired lack of effective diagnostic methods during the early stages of Interacting Genes. The enriched functions and pathways of the disease, the mortality rate of PCa remains high (10). of the identified DEGs included cell adhesion, the negative Therefore, it is crucial to understand the molecular mecha- regulation of cell proliferation, protein binding and focal adhe- nisms associated with PCa carcinogenesis, proliferation and sion.
    [Show full text]
  • Chromosome 8P As a Potential Hub for Developmental Neuropsychiatric
    Molecular Psychiatry (2009) 14, 563–589 & 2009 Nature Publishing Group All rights reserved 1359-4184/09 $32.00 www.nature.com/mp FEATURE REVIEW Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer R Tabare´s-Seisdedos1 and JLR Rubenstein2 1Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, CIBER-SAM, University of Valencia, Valencia, Spain and 2Nina Ireland Laboratory of Developmental Neurobiology, Department of Psychiatry, University of California, San Francisco, CA, USA Defects in genetic and developmental processes are thought to contribute susceptibility to autism and schizophrenia. Presumably, owing to etiological complexity identifying suscept- ibility genes and abnormalities in the development has been difficult. However, the importance of genes within chromosomal 8p region for neuropsychiatric disorders and cancer is well established. There are 484 annotated genes located on 8p; many are most likely oncogenes and tumor-suppressor genes. Molecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson’s and Alzheimer’s disease) and cancer. Furthermore, at least seven nonprotein- coding RNAs (microRNAs) are located at 8p. Structural variants on 8p, such as copy number variants, microdeletions or microduplications, might also contribute to autism, schizophrenia and other human diseases including cancer. In this review, we consider the current state of evidence from cytogenetic, linkage, association, gene expression and endophenotyping studies for the role of these 8p genes in neuropsychiatric disease.
    [Show full text]
  • Gene Expression and Coexpression Alterations Marking Evolution of Bladder Cancer
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.15.21258890; this version posted June 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Rafael Stroggilos1,3, Maria Frantzi2, Jerome Zoidakis1, Emmanouil Mavrogeorgis1÷, Marika 2 Mokou2, Maria G Roubelakis3,4, Harald Mischak2, Antonia Vlahou1* 3 1. Systems Biology Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. 4 2. Mosaiques Diagnostics GmbH, Hannover, Germany. 5 3. Laboratory of Biology, National and Kapodistrian University of Athens, School of Medicine, Athens, 6 Greece 7 4. Cell and Gene Therapy Laboratory, Biomedical Research Foundation of the Academy of Athens, Athens, 8 Greece. 9 ÷current address: Mosaiques Diagnostics GmbH, Hannover, Germany 10 * Corresponding author: 11 Antonia Vlahou, PhD 12 Biomedical Research Foundation, Academy of Athens 13 Soranou Efessiou 4, 14 11527, Athens, Greece 15 Tel: +30 210 6597506 16 Fax: +30 210 6597545 17 E-mail: [email protected] 18 19 TITLE 20 Gene expression and coexpression alterations marking evolution of bladder cancer 21 22 ABSTRACT 23 Despite advancements in therapeutics, Bladder Cancer (BLCA) constitutes a major clinical 24 burden, with locally advanced and metastatic cases facing poor survival rates. Aiming at 25 expanding our knowledge of BLCA molecular pathophysiology, we integrated 1,508 publicly 26 available, primary, well-characterized BLCA transcriptomes and investigated alterations in 27 gene expression with stage (T0-Ta-T1-T2-T3-T4).
    [Show full text]
  • PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer
    Research Article PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer Jae-Hyun Park, Meng-Lay Lin, Toshihiko Nishidate, Yusuke Nakamura, and Toyomasa Katagiri Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan Abstract to discover candidate target molecules for development of Breast cancer is one of the most common cancers among diagnosis and treatment of cancer (2). Through genome- women. To discover molecular targets that are applicable for wide expression analysis, we have isolated a number of oncogenes development of novel breast cancer therapy, we previously did that were involved in development and/or progression of genome-wide expression profile analysis of 81 breast cancers hepatocellular carcinomas (3, 4), synovial sarcomas (5, 6), and found dozens of genes that were highly and commonly and renal cell carcinomas (7). Such molecules are considered to up-regulated in breast cancer cells. Among them, we here be good candidate molecules for development of new therapeutic focused on one gene that encodes PDZ-binding kinase/T-LAK modalities. cell-originated protein kinase (PBK/TOPK), including a kinase Because cytotoxic drugs often cause severe adverse reactions, it domain. Northern blot analyses using mRNAs of normal is obvious that thoughtful selection of novel target molecules on the basis of well-characterized mechanisms of action should be human organs, breast cancer tissues, and cancer cell lines indicated this molecule to be a novel cancer/testis antigen. very helpful to develop effective anticancer drugs with the Reduction of PBK/TOPK expression by small interfering RNA minimum risk of side effects.
    [Show full text]
  • Single Cell Transcriptome Sequencing Reveals the Potential Mechanism of Heterogeneity in Immunoregulatory Function Between Mesenchymal Stromal Cells
    Single Cell Transcriptome Sequencing Reveals the Potential Mechanism of Heterogeneity in Immunoregulatory Function Between Mesenchymal Stromal Cells Siyu Cai Second Aliated Hospital of Shantou University Medical College Chuiqin Fan Second Aliated Hospital of Shantou University Medical College Lichun Xie Shenzhen Children's Hospital Huifeng Zhong Second Aliated Hospital of Shantou University Medical College Aijia Li Second Aliated Hospital of Shantou University Medical College Siyu Lv Shenzhen Children's Hospital Maochuan Liao Second Aliated Hospital of Shantou University Medical College Xixi Yang Shenzhen Children's Hospital Xing Su Second Aliated Hospital of Shantou University Medical College Yue Wang Shenzhen Children's Hospital Hongwu Wang Second Aliated Hospital of Shantou University Medical College Manna Wang Shenzhen Children's Hospital Peng Huang Shenzhen Children's Hospital Yulin Liu Second Aliated Hospital of Shantou University Medical College Yu Wang Shenzhen Children's Hospital Page 1/30 Yufeng Liu Zhengzhou University First Aliated Hospital Tianyou Wang Beijing Children's Hospital Capital Medical University Yong Zhong Dongguan Tangxia Hospital Lian Ma ( [email protected] ) Shenzhen Children's Hospital Research Article Keywords: Mesenchymal stromal cells, single cell transcriptome sequencing, the heterogeneity of immunomodulatory function, foreskin mesenchymal stromal cells, human umbilical cord mesenchymal stromal cells Posted Date: August 23rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-823639/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/30 Abstract Background: Mesenchymal stromal cells (MSCs) could be applied for the treatment of immune-related diseases. However, some studies have found there is enormous heterogeneity in immunomodulatory function of MSCs isolated from different tissue.
    [Show full text]
  • A Novel Loss-Of-Function Mutation of PBK Associated with Human Kidney
    www.nature.com/scientificreports OPEN A novel loss-of-function mutation of PBK associated with human kidney stone disease Choochai Nettuwakul1, Nunghathai Sawasdee1, Oranud Praditsap2, Nanyawan Rungroj2, Arnat Pasena1, Thanyaporn Dechtawewat1, Nipaporn Deejai1, Suchai Sritippayawan3, Santi Rojsatapong4, Wipada Chaowagul4 & Pa-thai Yenchitsomanus1 ✉ Kidney stone disease (KSD) is a prevalent disorder that causes human morbidity worldwide. The etiology of KSD is heterogeneous, ranging from monogenic defect to complex interaction between genetic and environmental factors. Since mutations of genes responsible for KSD in a majority of families are still unknown, our group is identifying mutations of these genes by means of genomic and genetic analyses. In this study, we identifed a novel loss-of-function mutation of PBK, encoding the PDZ binding kinase, that was found to be associated with KSD in an afected Thai family. Glycine (Gly) substituted by arginine (Arg) at position 43 (p.Gly43Arg) in PBK cosegregated with the disease in afected members of this family, but was absent in 180 normal control subjects from the same local population. Gly43 is highly evolutionarily conserved in vertebrates, and its substitution afects protein structure by alterations in H-bond forming patterns. This p.Gly43Arg substitution results in instability of the variant PBK protein as examined in HEK293T cells. The variant PBK protein (p.Gly43Arg) demonstrated decreased kinase activity to phosphorylate p38 MAPK as analyzed by immunoblotting and antibody microarray techniques. Taken together, these fndings suggest a possible new mechanism of KSD associated with pathogenic PBK variation. Human kidney stone disease (KSD) is a group of common disorders that cause morbidity in human populations and a global public health burden1.
    [Show full text]
  • The FEZ1 Gene at Chromosome 8P22 Encodes a Leucine-Zipper Protein, and Its Expression Is Altered in Multiple Human Tumors
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3928–3933, March 1999 Medical Sciences The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors HIDESHI ISHII*, RAFFAELE BAFFA*, SHIN-ICHIRO NUMATA*, YOSHIKI MURAKUMO*, SHASHI RATTAN*, HIROSHI INOUE†,MASAKI MORI†,VINCENZO FIDANZA*, HANSJUERG ALDER*, AND CARLO M. CROCE*‡ *Kimmel Cancer Institute, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107; and †Medical Institute of Bioregulation, Kyushu University, Beppu 874, Japan Communicated by Sidney Weinhouse, Jefferson Medical College, Philadelphia, PA, January 13, 1999 (received for review November 27, 1998) ABSTRACT Alterations of human chromosome 8p occur been studied in cancer, because of their carcinogen- frequently in many tumors. We identified a 1.5-Mb common metabolizing action (29, 30). The results showed no abnor- region of allelic loss on 8p22 by allelotype analysis. cDNA mality in cancer cells (29, 30). selection allowed isolation of several genes, including FEZ1. Esophageal cancer occurs worldwide, and its incidence is The predicted Fez1 protein contained a leucine-zipper region increasing in the Western world (31–33). We performed with similarity to the DNA-binding domain of the cAMP- allelotyping to identify a common region of loss at 8p in responsive activating-transcription factor 5. RNA blot analy- primary esophageal squamous cell carcinomas. We identified sis revealed that FEZ1 gene expression was undetectable in a common region of LOH at 8p22 around marker D8S261, more than 60% of epithelial tumors. Mutations were found in which overlaps with the target region in other tumors, includ- primary esophageal cancers and in a prostate cancer cell line.
    [Show full text]